Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
Information source: National Eye Institute (NEI)
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Retinitis Pigmentosa
Intervention: Lutein (Drug); Cornstarch control (Dietary Supplement)
Phase: Phase 3
Status: Completed
Sponsored by: National Eye Institute (NEI) Official(s) and/or principal investigator(s): Eliot L Berson, MD, Study Chair, Affiliation: Harvard Medical School
Summary
The purpose of this trial is to determine whether lutein in addition to vitamin A will slow
the course of retinitis pigmentosa.
Clinical Details
Official title: Randomized Clinical Trial for Retinitis Pigmentosa
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Central Visual Field (vf) Change Assessed Using the 30-2 Program of the Humphrey Field Analyzer (HFA).
Secondary outcome: Mid-peripheral Field Change Assessed With the 60-4 Program of the Humphrey Field Analyzer.Total Field Change Assessed by the Combined 30-2 and 60-4 Programs of the Humphrey Field Analyzer. Annual Change in 30 Hertz(Hz)Electroretinogram(ERG )Amplitude in Natural Log (ln) Microvolts/yr Over a 4 Year Period. Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity
Detailed description:
Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide
prevalence of approximately 1 in 4,000. Patients typically report night blindness and
difficulty with mid-peripheral visual field in adolescence. As the condition progresses,
they lose far peripheral visual field. Most patients have reductions in central vision by 60
years if left untreated. Vitamin A palmitate, 15,000 International Units (IU)/d and an
omega-3 rich diet have been shown to slow the progression of this condition among adults
with the typical forms.(see Archives of Ophthalmology,111: 761-772,1993 ; Archives of
Ophthalmology 122: 1306-1314, 2004; Archives of Ophthalmology 130(6):701-711,2013).
The present study was a randomized, controlled, double-masked trial with a planned duration
of 5 years. Two hundred and forty adults with the typical forms of RP were assigned to either
lutein 12mg/d or a control group. Patients in both groups received 15,000 IU/day of vitamin
A palmitate in addition to the supplement under study. Participants agreed not to know the
contents of the supplement or their group assignment until the end of the trial. The main
outcome measurement was the total point score for the 30-2 program of the Humphrey Field
analyzer (HFA). In addition,the total point score for the 60-4 program ,the total point
score of the 30-2 and 60-4 programs combined, computer-averaged 30-Hz cone Electroretinogram
(ERG) amplitude and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity were
measured annually as secondary endpoints.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Ocular Criteria
- RP, typical forms(i. e. elevated final dark adaptation threshold,retinal arteriolar
narrowing,and reduced and delayed full-field ERGs).
- Best-corrected visual acuity 20/100 or better
- HFA program 30-2 total point score >= 250 decibels(dB)to a size V white test light
- No confounding ocular disease such as glaucoma,uveitis,diabetic retinopathy,posterior
subcapsular cataract more than 11% of total lens area (ie equivalent to P3 on Lens
Opacity Classification System III)and pupil diameter after dilation less than 6 mm.
Dietary Criteria
- Fruit and vegetable intake < 10 servings/d
- Spinach or kale intake < 1 serving/d, i. e. <1/2 cup of cooked spinach or kale per day
- Dietary lutein intake <=5. 4 mg/d as estimated from food frequency questionnaire
- No intake of cod liver oil or omega-3 capsules
- Dietary preformed vitamin A intake <= 10,000 IU/d
- Supplement intake <= 5,000 IU/d of Vitamin A and <= 30 IU/d of Vitamin E
- Consumption <= 3 alcoholic beverages/d
Medical and other criteria
- Age 18-60 y
- Body mass index < 40 and weight >= 5th percentile for age,gender,and height
- Serum retinol level <= 100 micrograms/deciliter and serum retinyl ester level <= 380
nanomoles/Liter
- Serum cholesterol < 300 micrograms/deciliter and serum triglyceride level <400
micrograms/deciliter
- No clinically significant abnormality on blood cell count, glucose level, blood urea
nitrogen level, serum lipid panel results or serum liver function profile.
- Not pregnant or planning to become pregnant
- Not smoking currently
- Agreed not to know tablet content or course of condition until the end of the trial.
- No other disease which might affect absorption or metabolism of lutein or vitamin A.
- Only one patient per family was accepted into the study.
Exclusion Criteria:
- Women who are pregnant or planning to become pregnant (Vitamin A supplements can
increase the risk of birth defects.)
- Current participation in another clinical trial for RP
- Patients with atypical forms such as paravenous RP, pericentral RP, sector
RP,unilateral RP,Refsum disease, Bardet-Biedl syndrome, retinitis punctata albescens
and cone-rod dystrophy were excluded as were patients with RP and profound congenital
deafness.
Locations and Contacts
Berman Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School ,Massachusetts Eye & Ear Infirmary, Boston, Massachusetts 02114, United States
Additional Information
Starting date: July 2003
Last updated: December 12, 2013
|